3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Breast
1
Conditions
Breast Neoplasms
9
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Rectal Neoplasms
2
Neoplasms
2
Lung Neoplasms
2
Liver Neoplasms
2
Glioma
2
Disease
2
Carcinoma in Situ
2
Brain Neoplasms
2
Vulvar Neoplasms
1
Vulvar Diseases
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Sarcoma
1
Rhabdomyosarcoma
1
Prostate Cancer, Hereditary, 7
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Papillomavirus Infections
1
Oropharyngeal Neoplasms
1
Muscle Weakness
1
Lymphoma, Non-Hodgkin
1
Kidney Neoplasms
1
Inflammatory Breast Neoplasms
1
Hypoxia
1
Interventions
Cyclophosphamide
18
fludarabine phosphate
12
pembrolizumab
11
Nivolumab
11
Brentuximab Vedotin
11
Mycophenolic Acid
10
Doxorubicin
10
fludarabine
9
Dacarbazine
9
Whole-Body Irradiation
8
Etoposide
8
Vinblastine
7
Specimen Handling
7
Magnetic Resonance Spectroscopy
7
Filgrastim
7
Cyclosporine
7
Granulocyte Colony-Stimulating Factor
6
Sirolimus
5
Radiotherapy
5
Peripheral Blood Stem Cell Transplantation
5
Melphalan
5
Gemcitabine
5
Busulfan
5
Tacrolimus
4
pegfilgrastim
3
Vinorelbine
3
Stem Cell Transplantation
3
Rituximab
3
Radiation
3
Prednisone
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hodgkin Disease
×
Magnetic Resonance Imaging
×
90 days
×
Clear all
NCT05595577
2026-03-20
PALS
Wake Forest University Health Sciences
Phase NA
Recruiting
110 enrolled